Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer

被引：1

作者：

Akinsola, Olutiwa A. ^{[1
]}

Talwar, Ruchika ^{[1
]}

Baskin, Avi ^{[1
]}

Luckenbaugh, Amy N. ^{[1
]}

Awamlh, Bashir Al Hussein Al ^{[2
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA

[2] Weill Cornell Med, Dept Urol, 525 East 68th St,Starr 900, New York, NY 10065 USA

来源：

TRANSLATIONAL ANDROLOGY AND UROLOGY | 2024年 / 13卷 / 06期

关键词：

Bacillus Calmette-Gu & eacute; rin (BCG); high-risknon-muscle invasive bladder cancer (high-risk NMIBC); immunotherapy; atezolizumab; SINGLE-ARM; OPEN-LABEL; BCG; PEMBROLIZUMAB; MULTICENTER; CG0070;

D O I：

10.21037/tau-23-630

中图分类号：

R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

摘要：

Treatment options for patients with high-risk non-muscle invasive bladder cancer (NMIBC) who are unfit or unwilling to undergo radical cystectomy remain limited (1). Due to the lack of treatment options for this group of patients, especially in light of the continued global bacillus Calmette-Guérin (BCG) shortage (2), both the American Urological Association and the Food and Drug Administration (FDA) deemed single-arm phase 2 or 3 trials to be sufficient for approval of alternative treatment options into patient care. As of December 2022, intravesical valrubicin, intravenous pembrolizumab, and intravesical nadofaragene firadenovec remain the only FDA-approved treatments for BCG-unresponsive high-risk NMIBC. © Translational Andrology and Urology. All rights reserved.

引用

页码：1061 / 1063

页数：3

共 14 条

[1] Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer [J].

Al Awamlh, Bashir Al Hussein ;

Chang, Sam S. .

CURRENT ONCOLOGY REPORTS, 2023, 25 (02) :83-91

[2]

Al Hussein Al Awamlh B, 2023, ASCO Daily NewsJanuary 18,

[3] Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study [J].

Balar, Arjun, V ;

Kamat, Ashish M. ;

Kulkarni, Girish S. ;

Uchio, Edward M. ;

Boormans, Joost L. ;

Roumiguie, Mathieu ;

Krieger, Laurence E. M. ;

Singer, Eric A. ;

Bajorin, Dean F. ;

Grivas, Petros ;

Seo, Ho Kyung ;

Nishiyama, Hiroyuki ;

Konety, Badrinath R. ;

Li, Haojie ;

Nam, Kijoeng ;

Kapadia, Ekta ;

Frenkl, Tara ;

de Wit, Ronald .

LANCET ONCOLOGY, 2021, 22 (07) :919-930

[4] Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin- unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605 [J].

Black, Peter C. ;

Tangen, Catherine M. ;

Singh, Parminder ;

McConkey, David J. ;

Lucia, M. Scott ;

Lowrance, William T. ;

Koshkin, Vadim S. ;

Stratton, Kelly L. ;

Bivalacqua, Trinity J. ;

Kassouf, Wassim ;

Porten, Sima P. ;

Bangs, Rick ;

Plets, Melissa ;

Thompson, Ian M. ;

Lerner, Seth P. .

EUROPEAN UROLOGY, 2023, 84 (06) :536-544

[5] Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial [J].

Boorjian, Stephen A. ;

Alemozaffar, Mehrdad ;

Konety, Badrinath R. ;

Shore, Neal D. ;

Gomella, Leonard G. ;

Kamat, Ashish M. ;

Bivalacqua, Trinity J. ;

Montgomery, Jeffrey S. ;

Lerner, Seth P. ;

Busby, Joseph E. ;

Poch, Michael ;

Crispen, Paul L. ;

Steinberg, Gary D. ;

Schuckman, Anne K. ;

Downs, Tracy M. ;

Svatek, Robert S. ;

Mashni, Joseph, Jr. ;

Lane, Brian R. ;

Guzzo, Thomas J. ;

Bratslavsky, Gennady ;

Karsh, Lawrence I. ;

Woods, Michael E. ;

Brown, Gordon ;

Canter, Daniel ;

Luchey, Adam ;

Lotan, Yair ;

Krupski, Tracey ;

Inman, Brant A. ;

Williams, Michael B. ;

Cookson, Michael S. ;

Keegan, Kirk A. ;

Andriole, Gerald L., Jr. ;

Sankin, Alexander I. ;

Boyd, Alan ;

O'Donnell, Michael A. ;

Sawutz, David ;

Philipson, Richard ;

Coll, Ruth ;

Narayan, Vikram M. ;

Treasure, F. Peter ;

Yla-Herttuala, Seppo ;

Parker, Nigel R. ;

Dinney, Colin P. N. .

LANCET ONCOLOGY, 2021, 22 (01) :107-117

[6]

Castellano D, 2023, J CLIN ONCOL, V41

[7] A phase Ill, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guerin (BCG) versus BCG alone in high-risk, BCG-naive non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). [J].

De Santis, Maria ;

Abdrashitov, Ramil ;

Hegele, Axel ;

Kolb, Margaret ;

Parker, Suzanne ;

Redorta, Juan Palou ;

Nishiyama, Hiroyuki ;

Xiao, Feng ;

Gupta, Ashok Kumar ;

Shore, Neal D. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)

[8]

FDA CDER & Mccrayk, 2018, BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry

[9] Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines [J].

Flaig, Thomas W. ;

Spiess, Philippe E. ;

Abern, Michael ;

Agarwal, Neeraj ;

Bangs, Rick ;

Boorjian, Stephen A. ;

Buyyounouski, Mark K. ;

Chan, Kevin ;

Chang, Sam ;

Friedlander, Terence ;

Greenberg, Richard E. ;

Guru, Khurshid A. ;

Herr, Harry W. ;

Hoffman-Censits, Jean ;

Kishan, Amar ;

Kundu, Shilajit ;

Lele, Subodh M. ;

Mamtani, Ronac ;

Margulis, Vitaly ;

Mian, Omar Y. ;

Michalski, Jeff ;

Montgomery, Jeffrey S. ;

Nandagopal, Lakshminarayanan ;

Pagliaro, Lance C. ;

Parikh, Mamta ;

Patterson, Anthony ;

Plimack, Elizabeth R. ;

Pohar, Kamal S. ;

Preston, Mark A. ;

Richards, Kyle ;

Sexton, Wade J. ;

Siefker-Radtke, Arlene O. ;

Tollefson, Matthew ;

Tward, Jonathan ;

Wright, Jonathan L. ;

Dwyer, Mary A. ;

Cassara, Carly J. ;

Gurski, Lisa A. .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (08) :866-878

[10]

Hahn NM, 2020, J CLIN ONCOL, V38

← 1 2 →